NSE:BROOKS
BROOKS LAB LIMITED
₹59.01
at close · 21 Sept 2026
Latest filings
- Company Secretary and Compliance Officer resigns effective 9 October 2026 · Management Changes
- Newspaper notice for re-lodgement of physical share transfers · Compliance
- 24th AGM results: all 6 resolutions approved by over 99.99 percent votes · Board & Shareholder Meetings
- Brooks Labs 24th AGM held via video conferencing, 7 ordinary resolutions placed · Board & Shareholder Meetings
- Addendum to Notice of 24th Annual General Meeting · Compliance
- Addendum to 24th AGM notice - changes to Resolution No. 4 · Board & Shareholder Meetings
- Addendum to 24th AGM notice - revised related party transaction resolution · Board & Shareholder Meetings
- Brooks Laboratories announces book closure and e-voting dates for 24th AGM · Board & Shareholder Meetings
- Q1 FY27 Results: Standalone profit declines, consolidated swings to loss · Results
- Newspaper notice published for 24th AGM on 3 September 2026 · Compliance
- Letter to Shareholders - Annual Report FY 2025-26 and AGM Notice · Compliance
- Brooks Labs 24th AGM Notice - Sept 3, 2026 via Video Conferencing · Board & Shareholder Meetings
- 24th AGM notice published in newspapers for 3 September 2026 · Compliance
- Board meeting on 13 Aug to approve Q1 FY27 results · Results
- Brooks Lab appoints Rajesh Mahajan as President-Trading · Management Changes
- Brooks Labs signs binding MoU for partial BSL stake sale, expects INR 106.33 cr · Strategic Transactions
- Reg 74(5) compliance certificate for quarter ended June 2026 · Compliance
- Compliance certificate submitted to BSE and NSE for Q1 FY27 · Compliance
- Brooks Labs incorporates wholly owned subsidiary Abridge Speciality · Strategic Transactions
- Brooks Labs incorporates wholly owned subsidiary Abridge Speciality Ltd · Strategic Transactions
- Trading Window closure from July 1, 2026 ahead of Q1 results · Compliance
- Trading Window Closure from July 1, 2026 Ahead of Q1 Results · Compliance
- Brooks Labs sells 16.33% stake in Brooks Steriscience for Rs 106.33 cr · Ownership Changes
- Brooks Labs sells 16.33% stake in Brooks Steriscience for Rs 106.33 cr · Strategic Transactions
- Brooks Labs to sell 16.33% stake in Brooks Steriscience for Rs 106.33 cr · Strategic Transactions
- Brooks Labs sells 16.33 percent stake in Brooks Steriscience for Rs 106.33 crore · Strategic Transactions
- Newspaper Publication dated 30th May 2026 of Audited Financial Results for the quarter and year ended 31st March 2026. · Compliance
- Newspaper Publication dated 30th May 2026 of Audited Financial Results for the quarter and year ended 31st March 2026. · Compliance
- Brooks Laboratories Limited has informed the Exchange regarding Appointment of Mr Prashant Rathi as Chief Executive Officer of the company w.e.f. Jun 01, 2026. · Management Changes
- Brooks Laboratories Limited has submitted to the Exchange, the financial results for the quarter and year ended March 31, 2026. · Results
- Annual Secretarial Compliance Report of the financial year ended 31st March 2026 · Compliance
- Appointment of Chief Executive Officer. · Management Changes
- Outcome of Board Meeting held on Held On Friday, 29th May 2026. · Results
- Outcome of the Board Meeting held on Friday, 29th May 2026 · Results
- Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve and take on record the .... · Board & Shareholder Meetings
- Update On Scheme Of Arrangement Involving Brooks Steriscience Limited ('BSL'), A Joint Venture / Associate Of The Company. · Strategic Transactions
- Update on Scheme of Arrangement involving Brooks Steriscience Limited ("BSL"), a Joint Venture / Associate of the Company. · Strategic Transactions
- Brooks Labs confirms non-applicability of Large Corporate framework for FY26 · Compliance
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 31st March 2026. · Compliance
- Atul Ranchal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. · Ownership Changes
- Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Brooks Laboratories Limited has submitted their response. · Compliance
- Significant movement in price has been observed in Brooks Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. · Compliance
- Brooks Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
- Newspaper publication regarding the Special Window open for re-lodgement of transfer deeds · Compliance
- Update On Scheme Of Arrangement Involving Brooks Steriscience Limited ('BSL'), A Joint Venture / Associate Of The Company. · Strategic Transactions
- Brooks Laboratories Limited has informed the Exchange about Copy of Newspaper Publication · Compliance
- Brooks Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. · Results
- Disclosure Under Regulation 30 Of SEBI (LODR) Regulation, 2015- ITAT Orders. · Regulatory & Legal
- Brooks Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve and take on record the .... · Results
- Brooks Laboratories Limited has informed the Exchange about Compliance Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018 for the quarter ended 31st December 2025. · Compliance
Snapshot
What the business is, and whether it's a good one at a fair price.
A listed company listed on NSE and BSE, reporting revenue of ₹83 Cr over the trailing twelve months.
Market Cap
₹174 Cr
P / E (TTM)
13.1×
EV / EBITDA
25.2×
Div Yield
—
Growth
2.1%▲
Revenue 5y CAGR
PAT — · EBITDA +45.6%
Quality
3.6%·
ROCE (5y median)
ROE -14.4% · margin 9.6%
Leverage
0.06·
Debt / Equity · low
Net debt ₹1 Cr
Revenue FY21→FY26
1.1×▲
Margin +53.8 pts
₹77 Cr → ₹86 Cr
Moves on a normal day
2.15%·
Median daily move
Last 268 sessions · filing days run larger
Scorecard
Measured from the filed financials · as of FY26 — not investment advice
Strengths
Debt at 0.06× equity
Concerns
Slow revenue growth — 2% a year over 5 years
Returns on capital 3.6% (5-year median)
up from -6.0% in FY21
Charts
How has the market priced it — with filings on the timeline?
BROOKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from BROOKS LAB LIMITED's filed financials and exchange disclosures
What does BROOKS LAB LIMITED do?
BROOKS LAB LIMITED is listed on NSE and BSE, trading under the symbol BROOKS.
Is BROOKS LAB LIMITED profitable?
Yes. Over the trailing twelve months BROOKS LAB LIMITED reported a net profit of ₹13 Cr on revenue of ₹83 Cr.
Does BROOKS LAB LIMITED pay a dividend?
Not in the latest reported year — BROOKS LAB LIMITED's dividend payout for FY26 was nil.
Is BROOKS LAB LIMITED debt-free?
No. Debt stands at 0.06× equity, and it carries net debt of ₹1 Cr.
How much does the BROOKS LAB LIMITED share price move in a day?
On a typical session BROOKS LAB LIMITED moves 2.15% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Where can I track BROOKS LAB LIMITED's announcements?
Every NSE and BSE filing by BROOKS LAB LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.